Lung Life Ai
Biotechnology, 2545 W Hillcrest Dr, Thousand Oaks, California, 91320, United States, 11-50 Employees
Phone Number: +12*********
Who is LUNGLIFE AI
LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact ...
Read More
- Headquarters: 2545 W Hillcrest Dr, Thousand Oaks, California, 91320, United States
- Employees: 11-50
- Revenue: $5 Million to $10 Million
- CEO: Paul Pagano
Industry: Biotechnology
SIC Code: 8071
Does something look wrong? Fix it. | View contact records from LUNGLIFE AI
LungLife AI Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding LungLife AI
Answer: LungLife AI's headquarters are located at 2545 W Hillcrest Dr, Thousand Oaks, California, 91320, United States
Answer: LungLife AI's phone number is +12*********
Answer: LungLife AI's official website is https://lunglifeai.com
Answer: LungLife AI's revenue is $5 Million to $10 Million
Answer: LungLife AI's SIC: 8071
Answer: LungLife AI has 11-50 employees
Answer: LungLife AI is in Biotechnology
Answer: LungLife AI contact info: Phone number: +12********* Website: https://lunglifeai.com
Answer: LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact in the early detection of lung cancer. The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve biomarker detection, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications designed to improve its diagnostic solutions over time. The Company's core technologies are integrated in the LungLB test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan. There are estimated to be over 1.5 million individuals with indeterminate lung nodules diagnosed each year in the United States. The LungLB test may have additional utilities, the most significant of which is likely to be in monitoring individuals for recurrence following surgical removal of cancerous lung nodules. The Company has completed a 149 subject pilot study to evaluate the LungLB test, which showed a well-balanced performance and a Positive Predictive Value of 89 per cent. The Company is now gearing up to proceed to a larger, multi-centre validation study to garner regulatory and reimbursement support and facilitate commercialisation.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month